Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK04 Fruquintinib
D11977 Fruquintinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors
Fruquintinib
D11977 Fruquintinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11977 Fruquintinib (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D11977 Fruquintinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D11977 Fruquintinib
DG01642 CYP2C9 substrate
D11977 Fruquintinib
DG01639 CYP2C19 substrate
D11977 Fruquintinib
DG01633 CYP3A/CYP3A4 substrate
D11977 Fruquintinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
VEGFR family
VEGFR1 (FLT1)
D11977 Fruquintinib (JAN/USAN) <JP/US>
VEGFR2 (KDR)
D11977 Fruquintinib (JAN/USAN) <JP/US>
VEGFR3 (FLT4)
D11977 Fruquintinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11977
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11977
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11977
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11977
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11977
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11977